0

A gene called DOT1L appears to play a role in progression and severity of ovarian cancer, and inhibitors of the DOT1L enzyme may offer a new therapeutic approach for the disease, researchers say in a new study. The need is clear — despite decades of work to develop new treatment modalities, the five-year survival of patients with advanced ovarian cancer is between 10 and 30 percent.

Source


Like it? Share with your friends!

0

What's Your Reaction?

hate hate
0
hate
confused confused
0
confused
fail fail
0
fail
fun fun
0
fun
geeky geeky
0
geeky
love love
0
love
lol lol
0
lol
omg omg
0
omg
win win
0
win
admin

0 Comments

Your email address will not be published. Required fields are marked *